阿玛琳 AMRN 深 沪
交易中 11-05 10:17:52 美东时间
12.10
-0.150
-1.22%
华盛通- 最 高12.23
- 今 开12.23
- 成交量 577股
- 最 低 12.10
- 昨 收 12.25
- 总市值 2.55亿
- 52周最高 17.31
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 11.25
- 委 比 42.86%
- 总股本 2107.32万
- 历史最高 522.40
- 量 比 0.09
- 振 幅 1.06%
- 历史最低 7.08
- 每 手 1
- 风险率 1.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多阿玛琳收涨0.17%，成交额120.99万美元
11月3日，阿玛琳（AMRN）收涨0.17%，报12.13美元，成交额120.99万美元，市值2.56亿美元。 行情数据 • 开盘价：12.11美元 • 最高价...
11-03 07:30
阿玛琳收涨2.54%，成交额77.87万美元
10月27日，阿玛琳（AMRN）收涨2.54%，报12.09美元，成交额77.87万美元，市值2.55亿美元。 行情数据 • 开盘价：12.04美元 • 最高价...
10-27 06:32
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
The EMT2 trial, a Phase 3 study evaluating VASCEPA in colorectal cancer liver metastases, did not meet its primary endpoint of progression-free survival (PFS) but showed a statistically significant improvement in overall survival (OS), reducing the risk of death by approximately 32% at 5 years. The drug was found to be safe and well-tolerated. Researchers noted that the OS benefit without a corresponding PFS benefit is not unprecedented in oncolo...
10-25 12:11
阿玛琳收跌2.16%，成交额129.13万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:38
美股大行评级 | 罗斯百货、迪尔股份获多家大行上调目标价；沃尔玛、Advance遭多家大行下调目标价
今日重点评级关注：摩根士丹利：维持Ultragenyx Pharmaceutical"超配"评级，目标价从67美元升至74美元；Truist Securities：维持Solid Biosciences"买入"评级，目标价从16美元升至20美元
08-24 16:40
JP Morgan Reinstates Underweight on Amarin Corp, Announces $13 Price Target
JP Morgan analyst Jessica Fye reinstates Amarin Corp (NASDAQ:AMRN) with a Underweight and announces $13 price target.
08-22 03:10
Amarin Corp Q2 Sales $42.211M Miss $44.550M Estimate
Amarin Corp (NASDAQ:AMRN) reported quarterly sales of $42.211 million which missed the analyst consensus estimate of $44.550 million by 5.25 percent. This is a 41.97 percent decrease over sales of $72.740 million the same period last year.
07-29 19:04
Amarin Highlights Recent FDA Approval Of Injectable Apolipoprotein C-III Therapies For Treatment Of Severe Hypertriglyceridemia, Defined As Triglycerides Greater Than Or Equal To 500 mg/dL
Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, applauds the recent FDA approval of injectable apolipoprotein C-III (APOC3) therapies for the treatment of severe hypertriglyceridemia (sHTG), defined as triglycerides (TG) greater...
07-01 04:18
U.S. Supreme Court Rules In Favor Of Hikma Pharmaceuticals V Amarin Pharmaceuticals Over Patent Infringement Claims By Amarin
https://www.supremecourt.gov/opinions/25pdf/24-889_5i36.pdf
06-04 22:10
Amarin Announces New Data From A Post Hoc Analysis Of The REDUCE-IT Trial; Apolipoprotein B More Effectively Identified Individuals At Increased Residual Cardiovascular Risk
Amarin Corporation plc (NASDAQ:AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced new data from a post hoc analysis of the REDUCE-IT® trial
05-27 20:03
